JP2009533021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009533021A5 JP2009533021A5 JP2009502214A JP2009502214A JP2009533021A5 JP 2009533021 A5 JP2009533021 A5 JP 2009533021A5 JP 2009502214 A JP2009502214 A JP 2009502214A JP 2009502214 A JP2009502214 A JP 2009502214A JP 2009533021 A5 JP2009533021 A5 JP 2009533021A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nucleotide sequence
- sequence selected
- substantial homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 20
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 239000011630 iodine Substances 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims 2
- 102100029337 Thyrotropin receptor Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0606276A GB0606276D0 (en) | 2006-03-29 | 2006-03-29 | Antibodies |
| GB0606276.4 | 2006-03-29 | ||
| GB0607376.1 | 2006-04-12 | ||
| GB0607376A GB0607376D0 (en) | 2006-04-12 | 2006-04-12 | Antibodies |
| PCT/GB2007/001139 WO2007110648A1 (en) | 2006-03-29 | 2007-03-29 | Agonist antibodies against tshr |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009533021A JP2009533021A (ja) | 2009-09-17 |
| JP2009533021A5 true JP2009533021A5 (enExample) | 2010-05-13 |
| JP5165672B2 JP5165672B2 (ja) | 2013-03-21 |
Family
ID=38093407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009502214A Active JP5165672B2 (ja) | 2006-03-29 | 2007-03-29 | Ｔｓｈｒに対するアゴニスト抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8603466B2 (enExample) |
| EP (1) | EP1999153B1 (enExample) |
| JP (1) | JP5165672B2 (enExample) |
| ES (1) | ES2482145T3 (enExample) |
| WO (1) | WO2007110648A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2617735A3 (en) * | 2008-12-24 | 2013-10-16 | Rsr Limited | Human anti tshr antibodies |
| US8785603B2 (en) | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| EP3380620B1 (en) | 2015-11-23 | 2024-07-03 | Novartis AG | Optimized lentiviral transfer vectors and uses thereof |
| CN109072195A (zh) | 2015-12-30 | 2018-12-21 | 诺华股份有限公司 | 具有增强功效的免疫效应细胞疗法 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| AU2018355427A1 (en) | 2017-10-25 | 2020-04-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| WO2019213282A1 (en) | 2018-05-01 | 2019-11-07 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US20240245670A1 (en) | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20220227875A1 (en) * | 2019-05-31 | 2022-07-21 | University Of Florida Research Foundation, Incorporated | Vector-based therapy for thyroid disease |
| KR20220116522A (ko) | 2019-12-20 | 2022-08-23 | 노파르티스 아게 | 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도 |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| KR102769147B1 (ko) * | 2022-06-10 | 2025-02-20 | 메디맵바이오 주식회사 | Tigit에 특이적으로 결합하는 항체 및 인터류킨-15를 포함하는 융합 단백질 및 이의 용도 |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69530415T2 (de) * | 1994-12-28 | 2004-02-12 | University Of Kentucky | Rekombinierte sequenzen des monoklonalen anti-idiotypischen antikörpers 3h1, diean dem menschlichen karzioembyonischen antigen liiert sind |
| US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
| MXPA02000264A (es) * | 1999-07-01 | 2002-06-21 | Procter & Gamble | Producto detergentes para el lavado automatico de vajillas, de tipo liquido en gel transparente o translucido. |
| CN101799476B (zh) | 2001-08-23 | 2013-01-02 | Rsr有限公司 | 筛选针对tsh受体的自身抗体的试剂盒 |
-
2007
- 2007-03-29 JP JP2009502214A patent/JP5165672B2/ja active Active
- 2007-03-29 WO PCT/GB2007/001139 patent/WO2007110648A1/en not_active Ceased
- 2007-03-29 US US12/294,760 patent/US8603466B2/en active Active
- 2007-03-29 ES ES07732193.3T patent/ES2482145T3/es active Active
- 2007-03-29 EP EP07732193.3A patent/EP1999153B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009533021A5 (enExample) | ||
| CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| RU2009126766A (ru) | Антитела человека к дельта-подобному лиганду-4 человека | |
| JP6983371B2 (ja) | 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途 | |
| JP2021535743A (ja) | 抗ｃｄ４７抗体及びその応用 | |
| RU2430112C2 (ru) | Композиции и способы диагностики и лечения опухоли | |
| JP5972871B2 (ja) | 抗ｉｌ−２３ヘテロ二量体特異的抗体 | |
| JP7173964B2 (ja) | 抗ｐ５３抗体 | |
| JP2009502171A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| RU2013107776A (ru) | Антитело к противоопухолевому антигену и способы применения | |
| WO2023206985A1 (en) | Ror1 antibody or ror1 /cd19 /cd3 tri-specific antibody for the treatment of tumors | |
| CN104144944A (zh) | 抗-脂阿拉伯甘露聚糖抗体和使用该抗体对抗酸杆菌感染的免疫测定 | |
| JP2013520174A5 (enExample) | ||
| JP2020530285A5 (enExample) | ||
| RU2010132647A (ru) | Анти-mif антитела | |
| RU2010104633A (ru) | НОВЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ ДИМЕРИЗАЦИЮ c-МЕТ, И ИХ ПРИМЕНЕНИЯ | |
| JP2011526785A5 (enExample) | ||
| JP2012523848A5 (enExample) | ||
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| CN106604932A (zh) | 人白细胞介素‑2的免疫刺激单克隆抗体 | |
| CN108178799B (zh) | 一种抗ca125糖类抗原的纳米抗体及其应用 | |
| RU2009120536A (ru) | Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf) |